Thor Petersen

Thor Petersen

Auto-generated profile, based on publicly available information

Thor Petersen

Department of Neurology, Aarhus University Hospital, Denmark

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in The Lancet Neurology
Verified
Journal Article
Closed access
AHAnna He
Anna He
BMBernd Merkel
Bernd Merkel
JBJames William L Brown
James William L Brown
LRLana Zhovits Ryerson
Lana Zhovits Ryerson
IKIlya Kister
Ilya Kister
TKTomas Kalincik
Tomas Kalincik

7 July 2016 in Brain
Verified
Journal Article
Open access
PDF file
JLJohannes Lorscheider
Johannes Lorscheider
KBKatherine Buzzard
Katherine Buzzard
VJVilija Jokubaitis
Vilija Jokubaitis
TSTim Spelman
Tim Spelman
EHEva Kubala Havrdová
Eva Kubala Havrdová
OGon behalf of the MSBase Study Group
on behalf of the MSBase Study Group
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32–33.6) after disease onset compared with the physicians’ diagnosis at 36 (35–39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.

1 October 2003 in The Lancet
Verified
Journal Article
Closed access
PSPer Soelberg Sorensen
Per Soelberg Sorensen
CRChristian Ross
Christian Ross
KCKatja Maria Clemmesen
Katja Maria Clemmesen
KBKlaus Bendtzen
Klaus Bendtzen
JFJette Lautrup Frederiksen
Jette Lautrup Frederiksen
NKNils Koch-Henriksen
Nils Koch-Henriksen

1 May 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
RKRaju Kapoor
Raju Kapoor
PHPei-Ran Ho
Pei-Ran Ho
NCNolan Campbell
Nolan Campbell
ICIh Chang
Ih Chang
ADAaron Deykin
Aaron Deykin
GZGreg Zarelli
Greg Zarelli

3 November 2009 in Neurology
Verified
Journal Article
Closed access
PDF file
UDU. Dalgas
U. Dalgas
ESEgon Stenager
Egon Stenager
JJJ. Jakobsen
J. Jakobsen
TPT. Petersen
T. Petersen
HHH. J. Hansen
H. J. Hansen
TIT. Ingemann-Hansen
T. Ingemann-Hansen
Objective: To test the hypothesis that lower extremity progressive resistance training (PRT) can improve muscle strength and functional capacity in patients with multiple sclerosis (MS) and to evaluate whether the improvements are maintained after the trial. Methods: The present study was a 2-arm, 12-week, randomized controlled trial including a poststudy follow-up period of 12 weeks. Thirty-eight moderately impaired patients with MS were randomized to a PRT exercise group (n = 19) or a control group (n = 19). The exercise group completed a biweekly 12-week lower extremity PRT program and was afterward encouraged to continue training. After the trial, the control group completed the PRT intervention. Both groups were tested before and after 12 weeks of the trial and at 24 weeks (follow-up), where isometric muscle strength of the knee extensors (KE MVC) and functional capacity (FS; combined score of 4 tests) were evaluated. Results: KE MVC and FS improved after 12 weeks of PRT in the exercise group (KE MVC: 15.7% [95% confidence interval 4.3–27.0], FS: 21.5% [95% confidence interval 17.0–26.1]; p < 0.05), and the improvements were better than in the control group (p < 0.05). The improvements of KE and FS in the exercise group persisted at follow-up after 24 weeks. Also, the exercise effects were reproduced in the control group during the 12-week posttrial PRT period. Conclusions: Twelve weeks of intense progressive resistance training of the lower extremities leads to improvements of muscle strength and functional capacity in patients with multiple sclerosis, the effects persisting after 12 weeks of self-guided physical activity. Level of evidence: The present study provides level III evidence supporting the hypothesis that lower extremity progressive resistance training can improve muscle strength and functional capacity in patients with multiple sclerosis.

1 March 2010 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
UDU. Dalgas
U. Dalgas
ESEgon Stenager
Egon Stenager
JJJ. Jakobsen
J. Jakobsen
TPT. Petersen
T. Petersen
HHHj Hansen
Hj Hansen
TIT. Ingemann-Hansen
T. Ingemann-Hansen
Fatigue occurs in the majority of multiple sclerosis patients and therapeutic possibilities are few. Fatigue, mood and quality of life were studied in patients with multiple sclerosis following progressive resistance training leading to improvement of muscular strength and functional capacity. Fatigue (Fatigue Severity Scale, FSS), mood (Major Depression Inventory, MDI) and quality of life (physical and mental component scores, PCS and MCS, of SF36) were scored at start, end and follow-up of a randomized controlled clinical trial of 12 weeks of progressive resistance training in moderately disabled (Expanded Disability Status Scale, EDSS: 3—5.5) multiple sclerosis patients including a Control group (n = 15) and an Exercise group (n = 16). Fatigue (FSS > 4) was present in all patients. Scores of FSS, MDI, PCS—SF36 and MCS—SF36 were comparable at start of study in the two groups. Fatigue improved during exercise by —0.6 (95% confidence interval (CI) —1.4 to 0.4) a.u. vs. 0.1 (95% CI —0.4 to 0.6) a.u. in controls (p = 0.04), mood improved by —2.4 (95% CI —4.1 to 0.7) a.u. vs. 1.1 (—1.2 to 3.4) a.u. in controls (p = 0.01) and quality of life (PCS—SF36) improved by 3.5 (95% CI 1.4—5.7) a.u. vs. —1.0 (95% CI —3.4—1.4) a.u. in controls (p = 0.01). The beneficial effect of progressive resistance training on all scores was maintained at follow-up after further 12 weeks. Fatigue, mood and quality of life all improved following progressive resistance training, the beneficial effect being maintained for at least 12 weeks after end of intervention.